A study comparing two Unani medicines, Qurs-e-Habis and Sharbat-e-Anjabar, for the treatment of heavy menstrual bleeding (periods) in women

A comparative study of Qurs-e-Habis with Sharbat-e-Anjabar in the management of Kasrat-e-Tams (excessive uterine bleeding) in menstruating women - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103190

Enrollment

Registered

2026-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

Intervention1: Sharbat-e-Anjbar: 20ml to 40ml once a day orally for 60 days Intervention2: Qurs-e-Habis: Two qurs twice a day orally for 60days Control Intervention1: Sharbat-e-Anjbar: 20ml once a da

Eligibility

Inclusion criteria

Inclusion criteria: Non-gravid, non-menopausal females aged 19 45 years will be included if they meet the following criteria: 1. Presenting with menorrhagia, defined as menstrual blood loss (MBL) more then 80 ml per cycle, assessed using the menstrual pictogram or PBAC method. 2. Menstrual bleeding lasting more than 6 days. 3. Regular menstrual cycles between 21 35 days. 4. MBL more then 80 ml in at least 2 out of 3 consecutive cycles. 5. PBAC score more then 100. 6. Endometrial thickness up to 18 mm.

Exclusion criteria

Exclusion criteria: Participants will be excluded if they have any of the following: 1. Heavy menstrual bleeding associated with structural or histological abnormalities, especially when accompanied by intermenstrual bleeding, post-coital bleeding, pelvic pain, or pressure symptoms. 2. Heavy menstrual bleeding since menarche. 3. Conditions where heavy menstrual bleeding is not the primary symptom (e.g., endometriosis). 4. Fibroid uterus, adenomyosis, or endometriosis (clinically or radiologically diagnosed). 5. Thyroid dysfunction (hypothyroidism or hyperthyroidism). 6. Moderate to severe anemia as per WHO grading. 7. Metorrhagia or other abnormal uterine bleeding patterns. 8. Personal or family history suggestive of coagulation or bleeding disorders. 9. Systemic or chronic diseases requiring long-term treatment (e.g., renal, hepatic, or cardiovascular disorders). 10. Malignancies of the reproductive system or any systemic cancer. 11. Current use of intrauterine contraceptive devices (IUCDs). 12. Use of hormonal contraceptives within the last 3 months. 13. Post-menopausal bleeding or current hormone replacement therapy (HRT). 14. Pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Kasrat-e-tams(excessive uterine bleeding)Timepoint: 60days	—

Secondary

Measure	Time frame
Haematological, USG & biochemical assessment for safety assessmentTimepoint: At base line, 6weeks & 3 days(if required) during treatment & 8 weeks & 4 days after treatment	—

Countries

India

Contacts

Public ContactDr Syeda Samreen Shirazi

Ayurvadic and Unani Tibbia College & Hospital, Karol Bagh New Delhi.

shahanaayub86@gmail.com7037881205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026